


## Synthesis of long peptides using pseudoproline dipeptides

**Fmoc-Aaa-Ser/Thr( $\Psi^{\text{Me,Me}}$ pro)-OH**



Mutter's pseudoproline dipeptides are highly effective tools for expediting the synthesis of difficult peptides by Fmoc solid phase methods [1, 2].

The majority of published papers which relate to pseudoprolines describe their use in overcoming problems in short highly aggregated sequences [3, 4]. However, the real benefits of employing pseudoprolines are really only realized when they are used routinely. Apart from the obvious advantage of avoiding costly repeat syntheses of failed sequences, their incorporation leads to overall improvements in acylation and deprotection kinetics, resulting in improved yields, purities and solubilities of crude products and easier HPLC purification with higher product return.

This is most easily demonstrated through the synthesis of long peptides, where incremental increases in reaction efficiencies can have remarkable influence on overall product purities, as illustrated by the examples given overleaf.

05-20-1000	<b>Fmoc-Ala-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1005	<b>Fmoc-Ala-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1010	<b>Fmoc-Asn(Trt)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g

05-20-1011	<b>Fmoc-Asp(OtBu)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1126	<b>Fmoc-Asp(OtBu)-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1115	<b>Fmoc-Gln(Trt)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1125	<b>Fmoc-Gln(Trt)-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1002	<b>Fmoc-Glu(OtBu)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1122	<b>Fmoc-Glu(OtBu)-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1127	<b>Fmoc-Gly-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1124	<b>Fmoc-Gly-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1119	<b>Fmoc-Ile-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1118	<b>Fmoc-Ile-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1004	<b>Fmoc-Leu-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1009	<b>Fmoc-Leu-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1003	<b>Fmoc-Lys(Boc)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1116	<b>Fmoc-Lys(Boc)-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1121	<b>Fmoc-Phe-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1128	<b>Fmoc-Phe-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1012	<b>Fmoc-Ser(tBu)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1117	<b>Fmoc-Ser(tBu)-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1130	<b>Fmoc-Trp(Boc)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1014	<b>Fmoc-Tyr(tBu)-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1001	<b>Fmoc-Val-Ser(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g
05-20-1006	<b>Fmoc-Val-Thr(<math>\Psi^{\text{Me,Me}}</math>pro)-OH</b>	1 g
		5 g

# Applications

## Synthesis of 80 residue FAS-related peptide

The synthesis of the following peptide was carried out with insertion of pseudoproline dipeptides at the points indicated in bold. A parallel synthesis performed using standard amino acid building blocks was terminated at 50 cycles as the desired peptide could not be detected in the crude product. These results are published in full in ref. [5].

AKIDEIKNDN VQ**DT**AEQKVQ LLRNWHQKVQ LLRNWHQLHG  
KKEAY**DT**LK DLKKANL**ST**L AEKI **QT**ILK DI**TS**DSE**NS**N EHKL**TS**EKDL 2




Figure 1: HPLC profiles of a) crude 80mer prepared using pseudoproline dipeptides; b) crude peptide after 50 cycles prepared using standard amino acid building blocks.

## Application 1: Synthesis of FAS-death domain related peptides

The peptides were assembled automatically using a ABI 431A peptide synthesizer on Rink amide MBHA resin, which had been pre-loaded with a mixture of Boc-Leu-OH/Fmoc-Leu-OH (2:1) to give a resin with an Fmoc loading of 0.2 mmol/g. All acylation reactions were carried out using a 10-fold excess of Fmoc-amino acid activated with 1 eq. of HATU® in the presence of DIPEA. A coupling time of 60 min was used throughout. Cleavage and side-chain deprotection was effected by treatment of the peptidyl resins with TFA/TIS/water 95:2.5:2.5 (5 ml) for 3 h. The peptides were isolated in the usual manner by evaporation and ether precipitation. The products were characterized by HPLC and ES-MS.

## Synthesis of Domain 1 peptide [6]

The synthesis of the following peptide was carried out without and with insertion of a pseudoproline dipeptide at the point indicated. The peptide prepared without use of the pseudoproline dipeptide was contaminated with considerable amounts of a truncation sequence arising from incomplete Fmoc removal at cycle 29. GRTCPKPDDL PFSTVVPLKT FYEPGEEITY SCKPGY**VS**RG GMRKFICPLT GLWPINTLKCTPRV




Figure 2: HPLC profiles of a) crude Domain 1 prepared using standard amino acid building blocks; b) crude Domain 1 prepared using a single pseudoproline dipeptide.

## Application 2: Synthesis of Domain 1 peptide

The peptides were assembled automatically using a ABI 433A peptide synthesizer on Fmoc-Val-Wang resin. All acylation reactions were carried out using a 8-fold excess of Fmoc-amino acid activated with 1 eq. of HATU® in the presence of DIPEA. A coupling time of 60 min was used throughout. Cleavage and side-chain deprotection was effected by treatment of the peptidyl resins with TFA/TIS/water 95:2.5:2.5 (5 ml) for 3 h. The peptides were isolated in the usual manner by evaporation and ether precipitation. The products were characterized by HPLC and ES-MS.

## References

1. M. Mutter, et al. (1995) *Pept. Res.*, **8**, 145.
2. T. Haack & M. Mutter (1992) *Tetrahedron Lett.*, **33**, 1589.
3. P. White, et al. in "Peptides 1998, Proc. of 25th European Peptide Symposium", Budapest, Akadémiai Kiadó, 1998, pp. 120.
4. W. R. Sampson, et al. (1999) *J. Pept. Sci.*, **5**, 403.
5. P. White, et al. (2003) *J. Pept. Sci.*, in press.
6. Results kindly provided by Sharon Walker, La Jolla Pharmaceutical Company. Present address: Dept. of Chemistry, Massachusetts Institute of Technology.

Merck Biosciences AG · Switzerland

Weidenmattweg 4

4448 Läufelfingen

Phone +41 (62) 285 2525

Fax +41 (62) 285 2520

[www.novabiochem.com](http://www.novabiochem.com)

Novabiochem is a brand of Merck Biosciences AG.  
An affiliate of Merck KGaA, Darmstadt, Germany

